D. Western Therapeutics Institute, Inc. provided consolidated earnings guidance for the year ending December 31, 2021. For the period, the company expects net sales to be of JPY 400 million. Operating loss expected to be of JPY 290 million. Loss attributable to owners of the parent expected to be of JPY 270 million. Loss per share expected to be of JPY 9.20.